Immunization Technologies: Time to Consider New Preventative Solutions for Respiratory Syncytial Virus Infections

• 2023

  Log in to bookmark this resource.

  Log in
• Catherine Weil-Olivier; David Salisbury; José Navarro-Alonso; Chryssoula Tzialla; Yan Zhang; Susanna Esposito
PMID: 37193673DOI: https://dx.doi.org/10.1080/21645515.2023.2209000

---

Access Resources

• Journal ArticleEN
• Ask aRCie About This Resource

About

This article commentary discusses new ways to prevent respiratory syncytial virus (RSV) infections in infants. It highlights the use of long-acting monoclonal antibodies, like nirsevimab, which offer protection during an infant's first RSV season. These antibodies work like vaccines but are considered passive immunization. It emphasizes the need for updated regulations to include these new methods in national immunization programs and ensure broad access for all infants. It also mentions ongoing research and potential future strategies, such as maternal vaccines, to further protect against RSV infections in young children.

---

Tags

Focus Area: Infectious Disease

Audience: Physicians

Emergency Management Stage: Preparedness (Prevention / Protection)

Bundles: Nirsevimab Library

Keywords: Antibodies, Monoclonal; Communicable Diseases; Immunization; Immunization, Passive; Infant; Respiratory Syncytial Virus Infections; Vaccines, Synthetic; Immunization Programs; Respiratory Syncytial Virus, Human

Institutions: Paris Cité University; Chatham House; Spanish Association of Vaccinology; Chinese Center for Disease Control and Prevention; University of Parma; Sapienza Università di Roma; Charité – Universitätsmedizin Berlin

---

More like this

Pediatric Behavioral Health During the COVID-19 Pandemic: Expert Advice for Preparedness, Response, and Recovery 2023 · Pediatric Pandemic Network (PPN), University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine Strategies Used by Children’s Hospitals During the 2022 Viral Respiratory Surge 2025 · Seattle Children's Hospital, Ann and Robert H. Lurie Children’s Hospital, University of California San Francisco, UCSF Benioff Children's Hospital, St. Joseph’s Health, Boston Children's Hospital, University of Washington, Pediatric Pandemic Network (PPN) Evaluation of Antibody-Based Preventive Alternatives for Respiratory Syncytial Virus: A Novel Multi-Criteria Decision Analysis Framework and Assessment of Nirsevimab in Spain 2024 · University Carlos III, BioMad, Fisabio-Public Health, Catholic University of Valencia, Instituto de Salud Carlos III, Weber Foundation

---

The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

---